ClinicalTrials.gg
RecruitingNCT05138029Updated Aug 1, 2023

Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation

A Phase 3 interventional study of Ranibizumab Injection [Lucentis] and Inner limiting membrane stripping in Diabetic Retinopathy, sponsored by Affiliated Hospital of Nantong University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Affiliated Hospital of Nantong University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies testing ranibizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Ranibizumab · Diabetic Retinopathy.

Planned enrollment
17th of 34
60 · median 57
Started
2021
with 1 other
Phase 3
9 of 34
1 open now
Registered
30th of 34
by date
Lead sponsor
1 of 34
Affiliated Hospital of Nantong University

Among the 34 studies testing ranibizumab in Diabetic Retinopathy, this one is the 17th largest by planned enrollment, is one of 2 that started in 2021, is one of 9 in phase 3, and was the 30th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 34 studies testing ranibizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing ranibizumab in Diabetic Retinopathy, or all of them as a file.
02

Study summary

Select Proliferative Proliferative diabetic retinopathy(PDR) patients who are planning to undergo vitrectomy for informed notification. After obtaining informed consent, vitrectomy will be performed. After hemorrhage is removed, the macular shape can be obtained through intraoperative optical coherence tomography (iOCT) real-time scanning. If the central Macular Thickness (CMT) of the patient is ≥250μm, random Enter the Anti-vascular endothelial growth factor (anti-VEGF) treatment group, the internal limiting membrane stripping group and the glucocorticoid treatment group for treatment, and compare the patients' visual acuity (1 day, 7 days, 1 month, 3 months, 6 months) and The thickness of the center of the macula, compare and observe its treatment effect.

Read the detailed description
  1. Test method:

    • Include suitable cases of diabetic retinopathy and macular edema Inclusion criteria: a. PDR patients with severe vitreous hemorrhage who cannot collect oct images and require vitrectomy b. Type 2 diabetes, aged 18\~80 years old c. Good blood sugar control (glycated hemoglobin \<8.3%) d. Sign the informed consent form voluntarily, and are willing and able to follow the outpatient visits and research procedures within the time specified in the trial Exclusion criteria: a. Exclude severe infections of conjunctiva, cornea, and sclera b. Combined with other retinal vascular diseases such as retinal vein occlusion c. Cardiorenal insufficiency d. Myocardial infarction or stroke occurred within 6 months ②Intraoperative real-time operation All patients underwent 25Gauge(25G) transplanter three-channel vitrectomy to remove cloudy vitreous or vitreous hemorrhage and posterior vitreous cortex. Through intraoperative oct, the macular area was observed in real time and the central macular thickness was measured. If central macular thickness (CMT) ≥ 250 μm, anti-VEGF, glucocorticoid, or internal limiting membrane peeling was randomly selected to treat macular edema.

      • Re-examine the effect of surgery after operation The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
03

Conditions studied

  • Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PDR patients with severe vitreous hemorrhage who cannot collect oct images and need vitrectomy
  • Type 2 diabetes, aged 18\~80 years old
  • Good blood sugar control ( \<8.3%)
  • Sign the form voluntarily, and are willing and able to follow the outpatient visits and research procedures within the time specified in the trial

Exclusion criteria

Exclusion Criteria:

  • Exclude severe infections of conjunctiva, cornea, and sclera
  • Combined with other retinal vascular diseases such as retinal vein occlusion
  • Cardiorenal insufficiency
  • Myocardial infarction or stroke occurred within 6 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Anti-VEGF treatment group

    Visual acuity and center thickness of the macula

    Drug: Ranibizumab Injection [Lucentis]

  • Experimental
    Inner limiting membrane stripping group

    Visual acuity and center thickness of the macula

    Procedure: Inner limiting membrane stripping

  • Experimental
    Glucocorticoid treatment group

    Visual acuity and center thickness of the macula

    Drug: Dexamethasone intravitreal implant

Interventions

  • DrugRanibizumabStudies of RanibizumabRanibizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.

    Also known as: Lucentis

  • ProcedureInner limiting membrane stripping

    The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.

  • The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.

    Also known as: Dexamethasone Implants

06

What researchers measure

Primary outcomes

  1. Review the patient's vision before surgery

    Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.

    Time frame: The day before the patient's surgery

Secondary outcomes

  1. Review the patient's vision for one day after surgery

    Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.

    Time frame: The patient's first day after surgery

  2. Review the patient's vision for 7 days after surgery

    Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.

    Time frame: 1st week after surgery

  3. Review the patient's vision for 1 month after surgery

    Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.

    Time frame: 4th week after surgery

  4. Review the patient's vision for 3 months after surgery

    Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.

    Time frame: 12th week after surgery

  5. Review the patient's vision for 6 months after surgery

    Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.

    Time frame: 24th week after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2023, 25 months after the start.

Of 21 phase 3 interventional studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 41. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Nov 30, 2021
StartActual
Nov 15, 2021
Primary completionEst.
Dec 2023
CompletionEst.
May 2024
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05138029
Lead sponsor
Affiliated Hospital of Nantong University
Responsible party
Sponsor
First posted
Nov 30, 2021
Start date
Nov 15, 2021
Primary completion
Dec 2023 (estimated)
Completion
May 2024 (estimated)
Last update
Aug 1, 2023

Study contacts

Rongrong Zhu, Master
Contact
zrreye@126.com
13809089545
Zhuojun Xie, Bachelor
Contact
2305908442@qq.com
19502558036
Rongrong Zhu, master
principal investigator · Affiliated Hospital of Nantong University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ranibizumab · Dexamethasone Intravitreal Implant

Start the discussion